| Name | Title | Contact Details |
|---|
Althea Technologies, Inc., based in San Diego, CA, is focused on reducing the time, risk, and overall cost of our partner's drug development efforts. We apply immediate resources, unsurpassed scientific expertise, and a vast knowledge of regulatory
Telesta Therapeutics is a biopharmaceutical company focused on the development, manufacturing and commercialization of transformative human therapeutics. Our main focus is on novel medicines that address major unmet medical needs, particularly in oncology. Our anchor product, MCNA, has completed a Phase III pivotal study in patients with non-muscle invasive bladder cancer that have failed the first line therapy, bacillus Calmette-Guérin (BCG). Telesta submitted a Biologics Licensing Application (BLA) for MCNA with the U.S. FDA on June 29, 2015 and is seeking, upon marketing approval in the U.S., to make MCNA available for patients and their physicians. Our ultimate goal is to transform the treatment landscape and prolong and improve the lives of those affected by bladder cancer, one of the most common types of cancers today.
Rich history mixed with innovative technology is an integral part of Flagler Hospital in historic St. Augustine, Florida. Since its founding in 1889, our private, not-for-profit facility has grown into a 335 bed, acute care center that is consistently recognized nationally for overall clinical excellence. The hospital has consistently ranked among the top 5% in the nation for clinical excellence and patient safety for nearly a decade and was Northeast Florida`s first hospital to receive the ANCC Magnet hospital award. Most recently, the hospital earned five stars for heart attack treatment, the Gold Seal of Approval™ from The Joint Commission for Primary Stroke Care Centers, Center of Excellence Designation for its Bariatric Surgery Center, and national accreditation for total knee and total hip replacement surgery.
Vi-Jon aims to offer our own branded products in particular specialized markets. Vi-Jon is proud to produce Germ-X, a leader among waterless antibacterial hand sanitizers.
At PanOptica, our aim is to develop new ocular therapies that help patients see their very best throughout their lives. Many patients with common eye diseases suffer debilitating vision loss, despite currently available treatments. At PanOptica, we understand the critical role vision plays in a patient`s quality of life. And we know the frustration eye care professionals face when they are unable to treat their patients successfully. Today, significant progress is being made in the field of ophthalmology, with small laboratories and large pharmaceutical companies alike exploring newer, more effective treatments for sight-threatening diseases. PanOptica seeks to license and develop these innovative therapeutics, which may include improvements to existing therapies or entirely new treatments for previously untreatable disorders. Our lead development compound, PAN-90806 , is a novel, small-molecule selective VEGF receptor antagonist that shows promise as a topical treatment for wet age-related macular degeneration and diabetic retinopathy.